ES2062330T3 - Conjugados. - Google Patents

Conjugados.

Info

Publication number
ES2062330T3
ES2062330T3 ES90301589T ES90301589T ES2062330T3 ES 2062330 T3 ES2062330 T3 ES 2062330T3 ES 90301589 T ES90301589 T ES 90301589T ES 90301589 T ES90301589 T ES 90301589T ES 2062330 T3 ES2062330 T3 ES 2062330T3
Authority
ES
Spain
Prior art keywords
hbcag
lys
polypeptide
particles
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90301589T
Other languages
English (en)
Inventor
David John Rowlands
Berwyn Ewart Clarke
Michael James Francis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2062330T3 publication Critical patent/ES2062330T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PARTICULAS (HBCAG) ANTIGENAS DEL NUCLEO DE LA HEPATITIS B, QUE LLEVAN UN POLIPEPTIDO QUE PRESENTA UN EPITOPO ANTIGENICO Y QUE SON ADECUADAS PARA USO EN VACUNAS, SE COMPONE DE HBCAG PROVISTO CON UNA EXTENSION TERMINAL N QUE INCORPORA UN RESIDUO "LYS" Y EL MENCIONADO POLIPEPTIDO SE ACOPLA A LAS PARTICULAS POR MEDIO DEL GRUPO AMINO DE CADENA LATERAL DEL RESIDUO "LYS".
ES90301589T 1989-02-14 1990-02-14 Conjugados. Expired - Lifetime ES2062330T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898903313A GB8903313D0 (en) 1989-02-14 1989-02-14 Conjugates

Publications (1)

Publication Number Publication Date
ES2062330T3 true ES2062330T3 (es) 1994-12-16

Family

ID=10651663

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90301589T Expired - Lifetime ES2062330T3 (es) 1989-02-14 1990-02-14 Conjugados.

Country Status (11)

Country Link
EP (1) EP0385610B1 (es)
JP (1) JP2858848B2 (es)
AU (1) AU634518B2 (es)
CA (1) CA2009896A1 (es)
DE (1) DE69007311T2 (es)
DK (1) DK0385610T3 (es)
ES (1) ES2062330T3 (es)
GB (1) GB8903313D0 (es)
IE (1) IE64983B1 (es)
NZ (1) NZ232505A (es)
ZA (1) ZA901086B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2167304T3 (es) * 1987-06-22 2002-05-16 Medeva Holdings Bv Peptido que contiene el antigeno de superficie de la hepatitis b.
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
EP0563091A1 (en) * 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
FR2699538B1 (fr) * 1992-12-22 1995-02-03 Agronomique Inst Nat Rech Sous-unité d'une capsule protéique CS31A modifiée par au moins un peptide hétérologue, capsule protéique CS31A et microorganismes portant ces sous-unités; procédés d'obtention et utilisation de ceux-ci.
AU2540897A (en) * 1996-03-21 1997-10-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chimeric polypeptides for tumor antigen vaccines
IL137766A0 (en) * 1998-02-12 2001-10-31 Immune Complex Corp Strategically modified hepatitis b core proteins and their derivatives
EP1123114B1 (en) 1998-10-21 2005-12-28 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Virus-like particles for the induction of autoantibodies
MXPA01005389A (es) 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
CZ20011907A3 (cs) 1998-12-04 2002-01-16 Biogen, Inc. Částice jádra HBV s imunogenními sloľkami navázanými prostřednictvím peptidových ligandů
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
CN102061288A (zh) 2002-07-17 2011-05-18 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
BR0312297A (pt) 2002-07-18 2005-04-12 Cytos Biotechnology Ag Conjugados veìculos de hapteno e seu uso
SI1524994T1 (sl) 2002-07-19 2011-08-31 Cytos Biotechnology Ag Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
AU2004224762B2 (en) 2003-03-26 2009-12-24 Kuros Us Llc Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
US20060024670A1 (en) 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
ES2932952T3 (es) 2012-04-24 2023-01-30 Ohio State Innovation Foundation Composiciones y métodos para tratar y prevenir el síndrome reproductivo y respiratorio porcino
US10279028B2 (en) 2012-04-24 2019-05-07 Ohio State Innovation Foundation Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8421282D0 (en) * 1984-08-22 1984-09-26 Connaught Lab Multispecific antigenic proteins
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
GB8709274D0 (en) * 1987-04-16 1987-05-20 Wellcome Found Peptides

Also Published As

Publication number Publication date
EP0385610A1 (en) 1990-09-05
AU4975590A (en) 1990-10-18
CA2009896A1 (en) 1990-08-14
ZA901086B (en) 1990-11-28
IE900502L (en) 1990-08-14
IE64983B1 (en) 1995-09-20
DE69007311D1 (de) 1994-04-21
EP0385610B1 (en) 1994-03-16
DK0385610T3 (da) 1994-07-25
NZ232505A (en) 1992-12-23
JPH0327400A (ja) 1991-02-05
JP2858848B2 (ja) 1999-02-17
DE69007311T2 (de) 1994-06-23
AU634518B2 (en) 1993-02-25
GB8903313D0 (en) 1989-04-05

Similar Documents

Publication Publication Date Title
ES2062330T3 (es) Conjugados.
ES2129461T3 (es) Proteina hibrida entre cs de plasmodium y hbsag.
EA200100425A1 (ru) Новые способы терапевтической вакцинации
ES2075440T3 (es) Vacuna contra la hepatitis b.
ES2138784T3 (es) Antigenos sinteticos para la deteccion de anticuerpos contra el virus de la hepatitis c.
GB2255093A (en) Hiv-1 core protein fragments
ES2081102T3 (es) Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado.
NZ219113A (en) Hiv peptide containing epitope of the env protein
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
ES2074062T3 (es) Inmunoensayo para antigenos hiv-1 que utilizan fragmentos de f(ab')2 como sonda.
ES2013328A6 (es) Un metodo para detectar anticuerpos contra antigenos hiv-1.
ES8404186A1 (es) "un procedimiento para obtener al menos un polipeptido que presenta la antigenicidad de los antigenos e del virus de la hepatitis b".
DK461884A (da) Beskyttende peptidantigen
ES8608883A1 (es) Procedimiento de preparacion de un conjugado de muramilpeptido y de un hapteno o fragmento haptenico de bajo peso molecular.
AR004464A1 (es) Un metodo para producir una proteina de capside de papilomavirus
ES2137160T3 (es) Lipopeptidos inductores de los linfocitos t-citotoxicos y utilizacion como vacunas.
AR009365A1 (es) Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno
DE69007571D1 (de) Peptidfragmente von HIV.
ES8507100A1 (es) Un procedimiento para preparar oligopeptidos dimeros
IT1249684B (it) Epitopi della proteina env del virus dell'epatite c.
ATE72400T1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
OA09653A (en) Rubella peptides
NO881661L (no) Humane rhinoviruspeptider.
ES2037795T3 (es) Procedimiento para la preparacion del antigeno hrpii de plasmodium falciparum sge2.
ES2058240T3 (es) Nuevos peptidos sinteticos inmunologicamente activos utiles para la preparacion de una vacuna antimalarica.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 385610

Country of ref document: ES